Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider Buying at Marsh McLennan

Lloyd Yates, a member of Marsh & McLennan Companies, Inc. (NYSE:MMC)’s Board of Directors, purchased 4,000 shares of stock on March 22nd at an average price of $37.32 per share, according to a filing with the SEC. Marsh & McLennan provides insurance and consulting services and has a market capitalization of over $20 billion. We track insider purchases because it generally doesn’t make economic sense for insiders to increase their company-specific exposure rather than diversifying; in theory, then, a purchase should signal that the insider strongly believes that the company will do well. Studies of insider purchases show that they tend to narrowly outperform broader market indices (read our analysis of studies on insider trading).

The company’s 10-K shows that Marsh & McLennan Companies, Inc. experienced a 3% increase in revenue in 2012 compared to the previous year which is in line with the CAGR over the last four years. So going forward we would expect top line growth to continue to be low. However, over this four year period excellent cost management has resulted in an improvement in earnings each year: a loss in 2008, about $240 million in net income in 2009, and then growth up to $1.2 billion last year (representing 18% higher earnings than in 2011). While future earnings growth should be limited by the modest revenue numbers- Marsh & McLennan cannot grow through increasing margins forever- it could well be positive for some time. At a trailing P/E of 18, however, the market is setting a high bar for the company’s future earnings.

Andreas Halvorsen

Billionaire Tiger Cub Andreas Halvorsen’s Viking Global cut its stake in Marsh & McLennan Companies, Inc. by 52% in the fourth quarter of 2012, but the fund was still the largest holder of the stock in our database of 13F filings for the end of December at a position of 1.6 million shares (see Halvorsen’s stock picks). Adage Capital Management, which is co-managed by Phil Gross and Robert Atchinson, increased its holdings of the stock to a total of 1.1 million shares as of the end of 2012 (find Adage’s favorite stocks).

Peers for Marsh & McLennan’s insurance business include Aon PLC (NYSE:AON) and Willis Group Holdings PLC (NYSE:WSH). Aon trades at 21 times trailing earnings, placing it at a premium; however, Wall Street analyst estimates imply a forward P/E of 12, so they at least believe the company has better prospects than Marsh & McLennan. In the fourth quarter of 2012, Aon’s earnings were up 10% versus a year earlier though revenue growth was considerably lower. Willis, meanwhile, carries a forward P/E of 14, and in addition to being cheaper on that basis the stock also pays a slightly higher dividend yield- close to 3% going by current prices and recent dividend payments (Marsh & McLennan’s dividend yield is 3.5%). So in terms of valuation Marsh & McLennan isn’t too attractive as an insurance company.

What about the consulting side of the business?

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.